Table 1.
Baseline Characteristics of the Included Studies
| Study/Author | Year | Group | No. | Age, y | Women, % | Hypertension, % | Diabetes Mellitus, % | Hyperlipidemia, % | Obesity, % | Smoker, % | Follow Up, mo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RCTs | |||||||||||
| FLUVACS 17 | 2004 | Vaccine | 145 | 64.0 | 29.7 | 59.3 | 19.3 | … | … | 45.5 | 12 |
| No vaccine | 147 | 65.0 | 26.5 | 45.6 | 17.0 | … | … | 42.9 | |||
| FLUCAD 16 | 2008 | Vaccine | 325 | 58.8 | 28.9 | 69.7 | 19.8 | … | … | 20.7 | 12 |
| Placebo | 333 | 58.1 | 26.1 | 63.4 | 20.7 | … | … | 16.3 | |||
| IVCAD 18 | 2009 | Vaccine | 141 | 54.9 | 34.0 | 82.0 | … | 83.0 | … | … | 12 |
| Placebo | 137 | 54.5 | 33.0 | 84.0 | … | 90.0 | … | … | |||
| Phrommintikul et al 19 | 2011 | Vaccine | 221 | 65.0 | 39.0 | 63.1 | 29.0 | 44.3 | … | 13.7 | 12 |
| No Vaccine | 218 | 67.0 | 48.0 | 61.6 | 32.1 | 49.5 | … | 10.3 | |||
| Observational studies | |||||||||||
| de Diego et al 7 | 2009 | Vaccine | 860 | 76.7 | 52.0 | 66.7 | 32.1 | … | 24.0 | 6.5 | 40 |
| No vaccine | 480 | 75.5 | 53.8 | 60.6 | 32.7 | … | 17.7 | 8.1 | |||
| Liu et al 30 | 2012 | Vaccine | 2760 | 74.8 | 41.7 | 80.5 | 54.4 | 42.9 | … | … | 48 |
| No vaccine | 2288 | 75.7 | 48.2 | 76.2 | 53.2 | 38.8 | … | … | |||
| Wu et al 31 | 2014 | Vaccine | 2087 | 71.9 | 1.5 | … | … | … | … | … | 12 |
| No vaccine | 429 | 68.3 | 1.6 | … | … | … | … | … | |||
| Kopel et al 32 | 2014 | Vaccine | 501 | 75.8 | 44.0 | 73.0 | 45.0 | … | 23.0 | 32.0 | 48 |
| No vaccine | 1463 | 74.1 | 45.0 | 72.0 | 45.0 | … | 24.0 | 29.0 | |||
| Blaya‐Nováková et al 33 | 2016 | Vaccine | 1016 | 76.0 | 60.3 | 70.0 | 25.9 | 42.6 | 22.7 | … | 48 |
| No/partial vaccine | 1016 | 76.5 | 61.9 | 69.7 | 24.7 | 42.3 | 22.1 | … | |||
| Vardeny et al 10 | 2016 | Vaccine | 1769 | 67.9 | 19.8 | 68.9 | 40.9 | … | … | … | 27 |
| No vaccine | 6630 | 62.7 | 22.3 | 71.2 | 32.9 | … | … | … | |||
| Modin et al 34 | 2019 | Vaccine | 78 379 | 73.7 | 43.6 | 36.7 | 16.7 | … | … | … | 44.4 |
| No vaccine | 55 669 | 72.8 | 44.8 | 40.3 | 14.9 | … | … | … | |||
| Wu et al 20 | 2019 | Vaccine | 4350 | 76.3 | 35.1 | 90.1 | 53.7 | 57.6 | … | … | 12 |
| No vaccine | 4350 | 76.2 | 34.6 | 89.9 | 53.5 | 56.6 | … | … | |||
| Kaya et al 35 | 2016 | Vaccine | 265 | 60.0 | 28.3 | 35.1 | 24.0 | … | … | … | 15 |
| No vaccine | 391 | 63.0 | 27.6 | 34.3 | 21.0 | … | … | … | |||
| Jackson et al 36 | 2002 | Vaccine | 1016 | … | 34.9 | 49.3 | 24.1 | … | … | 23.3 | 27.6 |
| No vaccine | 362 | … | 27.3 | 42.8 | 17.1 | … | … | 41.4 | |||
| Lavallee et al 21 | 2014 | Vaccine | 5054 | 70.0 | 39.7 | 82.7 | 29.5 | 51.4 | … | 19.3 | 24 |
| No vaccine | 5054 | 69.9 | 40.0 | 82.9 | 29.9 | 51.6 | … | 19.5 | |||
| Mohseni et al 37 | 2017 | Vaccine | 59 202 | 74.7 | 49.9 | … | … | … | … | … | 12 |
| No vaccine | 74.7 | 49.9 | … | … | … | … | … | ||||
FLUCAD indicates Influenza Vaccination in Secondary Prevention From Coronary Ischemic Events in Coronary Artery Disease; FLUVACS, Flu Vaccination in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions; IVCAD, Efficacy of Influenza Vaccination in Reducing Cardiovascular Events in Patients With Coronary Artery Diseases; and RCTs, randomized control trials.